TY - JOUR ID - 18093 TI - Rifampicin-resistant tuberculosis in Iran: A systematic review and meta-analysis JO - Iranian Journal of Basic Medical Sciences JA - IJBMS LA - en SN - 2008-3866 AU - Bahraminia, Farhad AU - Azimi, Taher AU - Zangiabadian, Moein AU - Nasiri, Mohammad Javad AU - Goudarzi, Mehdi AU - Dadashi, Masoud AU - Imani Fooladi, Abbas Ali AD - Applied Microbiology research center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran AD - Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran AD - Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran AD - Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran Y1 - 2021 PY - 2021 VL - 24 IS - 6 SP - 720 EP - 725 KW - Drug resistance KW - Iran KW - rifampicin KW - Tuberculosis KW - Xpert MTB/RIF assay DO - 10.22038/ijbms.2021.47360.10901 N2 - Rifampicin (RIF)-resistant strain of Mycobacterium tuberculosis is an important barrier to effective tuberculosis (TB) treatment and prevention. The present study aimed to determine the frequency of RIF-resistant TB among patients with confirmed TB. Pubmed/Medline, Embase, Web of Science, and Scopus were searched for relevant articles published between January 1980 and January 2020. We pooled data with random-effects models when appropriate. After screening 1608 citations, 30 studies covering 8215 patients with TB were included. The pooled frequency of RIF-resistance among all patients with TB was 8.0% (95% CI 4.0–12.0). Our sub-group analysis showed that 4.0% of newly diagnosed cases and 36.0% of previously-treated TB patients from different settings in Iran were RIF-resistant. Our study showed that the frequency of RIF-resistance among patients with TB was 8.0%. Programmatic implementation of rapid drug susceptibility testing (DST) such as the Xpert MTB/RIF assay as a primary diagnostic test for persons suspected of having a RIF-resistant TB would be helpful for the control of the drug resistance.  UR - https://ijbms.mums.ac.ir/article_18093.html L1 - https://ijbms.mums.ac.ir/article_18093_5c4342755f2a081a210712e4d9c33935.pdf ER -